Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors

Figure 2

Inhibition of VEGF signaling pathways. Several classes of drugs have been developed to combat VEGF-mediated tumor angiogenesis. Monoclonal anti-VEGF antibodies (e.g., bevacizumab) and soluble receptor constructs (e.g., VEGF-Trap) bind to the VEGF and PlGF preventing their interaction and signaling through VEGFR1 and VEGFR2. Tyrosine kinase inhibitors (TKIs) inhibit the intracellular tyrosine kinase activity of VEGF receptors, blocking downstream signaling.